WHO Pharmaceuticals Newsletter 2005, No. 02
(2005; 22 pages) View the PDF document
Table of Contents
Open this folder and view contentsREGULATORY MATTERS
Close this folderSAFETY OF MEDICINES
View the documentAlimemazine - Paracetamol teething mixture - Contraindicated in children below two years
View the documentAmiodarone - Prescribers advised to be vigilant for serious adverse reactions
View the documentAripiprazole - Increases stroke risk among elderly dementia patients
View the documentAyurvedic Medicines - High levels of heavy metals in some preparations
View the documentCyclooxygenase (COX)-2 Inhibitors - Updated information
View the documentDrotrecogin alfa (activated) - Mortality in patients with single organ dysfunction and recent surgery
View the documentGalantamine - Additional safety assessment undertaken
View the documentMethotrexate - Fatal adverse effects reported
View the documentPergolide - Reports of valvular heart disease
View the documentRifampicin - Interaction with ritonavir-boosted saquinavir
View the documentTamoxifen - Increases risk of fatty liver disease in overweight women
View the documentTelithromycin - Adverse reactions update
View the documentTenofovir, Didanosine - New data on adverse events; coadministration not recommended in any ARV combination
View the documentTiagabine - Seizures following off-label use
Open this folder and view contentsDRUGS OF CURRENT INTEREST
Open this folder and view contentsFEATURE
 

Methotrexate - Fatal adverse effects reported

Japan. Doctors in Japan have reported 831 serious adverse effects associated with methotrexate (Rheumatrex) to Wyeth K.K., between March 1999 and November 2004; 134 reports were of fatal adverse effects, including interstitial pneumonia and myelosuppression. An estimated 100 000 people are taking methotrexate (Rheumatrex) in Japan.

Wyeth K.K. has warned doctors and patients that methotrexate (Rheumatrex) is associated with 'life-threatening' and 'sometimes serious' adverse effects, and has requested that the drug be used carefully. However, pharmaceutical experts have demanded that the manufacturer and the government clearly outline the risks associated with methotrexate.

Reference:

Japanese Media Release, 12 February 2005. Available on the internet at www.japantimes.co.jp

to previous section to next section
 

Last updated: May 3, 2013